{"analyses":[{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.28","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8175","pValueComment":"One-side significance level = 0.025","paramType":"Hazard Ratio (HR)","paramValue":"1.30","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.7","upperLimit":"88.3","value":"77.5"},{"groupId":"OG001","lowerLimit":"60.8","upperLimit":"77.8","value":"69.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"description":"Overall survival (OS) time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT+ Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"NUMBER","populationDescription":"Randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years.","title":"Overall Survival (Percentage of Participants Alive) [Originally Phase III Primary / Now Phase II Secondary]","type":"PRIMARY","unitOfMeasure":"percentage of participants"}